Essential Biomarker Testing in GI Cancers
- Author
- John L. Marshall MD
- Published
- Wed 18 Aug 2021
- Episode Link
- https://oncologypodcast.simplecast.com/episodes/gi-cancer-biomarker-testing-KOq2SA4w
In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:
- Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
- Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
- Colon cancer: RAS, BRAF, and HER2
- Gastric cancer: PD-L1, HER2, and more
- Pancreatic cancer: BRCA
- Biliary cancers: FGFR and IDH1
- Liquid biopsies
- When to test
Presenter:
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Content based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.
Link to full program:
https://bit.ly/3j4hV8J
